Table 1.
Medication adjustments for LCD meal plans summary of studies.
| Study | Type of medication | Adjustments made | Frequency of monitoring for medication adjustments |
|---|---|---|---|
| Yancy et al. (19) (n = 21) | Insulin | Reduced 50% upon starting diet. | Every other week for 16 weeks |
| Single-arm pilot intervention trialType 2 diabetes | Sulfonylureas | Reduced 50% or discontinued upon starting diet. | |
| Diuretics | Reduced 50%. Discontinued if on low dose (25 mg of hydrochlorothiazide or 20 mg of furosemide) upon starting diet. | ||
| Westman et al. (20) (n = 49)Prospective observational studyType 2 diabetes | Insulin | Discontinued or reduced from 12.5 to 90% at 24 weeks | Weekly for 3 months, then every other week for 3 months |
| Salow et al. (21) (n = 16)Parallel-group randomized trialType 2 diabetes and prediabetes | Sulfonylureas/DPP-4 inhibitors | All participants discontinued medications by 12 months post-baseline | Not specified |
| Athinarayanan et al. (6) (n = 267)Open label, non-randomized, controlled studyType 2 diabetes | Insulin Sulfonylureas | Total insulin reduced 62%Sulfonylureas reduced 100% | Continuous Care Intervention with remote patient monitoring |
| Saslow et al. (22) (n = 16)Parallel-group randomized trialType 2 diabetes and prediabetes | Sulfonylureas | Doses were reduced 50% if the entry HbA1c was <7.5%; discontinued if pre-dinner glucose levels went below 110 mg/dL in spite of prior dose reduction | Participants were asked to monitor fasting glucose and before dinner daily. Doctor visits unspecified. |
| Thiazolidinediones | Discontinued for those with starting HbA1c below 7%. | ||
| Metformin | Continued | ||
| Yabe et al. (18) (n = 24)Randomized, open-label, 3-arm parallel comparative exploratory studyType 2 diabetes | SGLT2 inhibitors | N/A. Discontinuation recommended. | Weekly |
| Unwin et al. (7) (n = 54 on DM meds)ongoing audit of service provision | Sulfonylureas, Insulin, Metformin,SGLT2i, GLP1a | Discontinued completely in 19 (35%) | Regular office visits w GP offices |
| Lean et al. (8) DiRECT (n = 148)111 on DM meds) 12 mos.Open-label, cluster-randomized trial | Not specified | Approx 75% taking meds both groups at start. 74% off all meds intervention group, 18% controls. | Regular office visits w GP offices |